Skip to main content
. Author manuscript; available in PMC: 2020 Nov 1.
Published in final edited form as: Antiviral Res. 2019 Aug 14;171:104590. doi: 10.1016/j.antiviral.2019.104590

Figure 1. CDDO-me is a dislocation inhibitor that may target grp94.

Figure 1.

(A) Time-lapse imaging of mutant α−1-antitrypsin protein (NHK) dislocation by drGFP in HeLa cells revealed that CDDO-me is an inhibitor of protein dislocation. Cells were treated with 1 µM bortezomib (BTZ) + 1 µM CDDO-me or DMSO (veh) and dislocation was monitored over 4 hrs (B) CDDO-me inhibited ER to cytosol dislocation of NHK at an IC50 of 0.39 µM. (C) Examining CDDO-me target engagement by CETSA. (D) Densitometric analysis of grp94 band intensities in CETSA were quantified and expressed as mean +/− SEM, n=3.